NASDAQ: PRME
Prime Medicine, Inc.
Healthcare · Biotechnology
Market Cap
$583.39M
52w High
$6.94
52w Low
$2.02
P/E
-2.88
Volume
3.19M
Outstanding Shares
180.62M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 79.44% over the last year. Revenue grew 4.89% over the trailing twelve months. Operating margin moved from -5,369.68% to -5,121.76%. Free cash flow declined 42.49% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher with no clear directional signal from operating metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at -5,121.76%. A decisive move in revenue — currently up 4.89% — would be the clearest signal to resolve the ambiguity.
Company profile
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
5
Buy
4
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Aug 6, 2026
Q3 FY26 · EPS est -$0.24 · Revenue est $2.37M
View